Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiracoxib in Primary Hip Osteoarthritis
NCT00154219Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of lumiracoxib in osteoarthritis (OA) (3 arms), sponsored by Novartis. Primary endpoints: WOMAC 3.1 LK questionnaire at 13 weeks and Patient's global assessment of disease activity at 13 weeks. Started Nov 2004; status: completed.
02
Drugs
lumiracoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00154219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154219.